Miist: A 30-Second Migraine Therapy

How do you treat a condition where timing determines efficacy? Join Miist CEO Dalton Signor for a deep dive into how the company is rethinking migraine treatment by solving for speed.

Migraine drugs are highly time-sensitive—when administered early, efficacy can exceed 90%, but most existing treatments act too slowly to capture this window. Miist is building a novel inhaler that delivers sumatriptan in ~30 seconds, enabling treatment before symptoms escalate and dramatically improving outcomes.

The company has already demonstrated rapid onset and safety in early human and animal studies, validating the core technology and de-risking key aspects of development.

In this session, we explore Miist’s path from clinical validation to approval, its strategy to leverage existing drug safety data for a faster regulatory pathway, and how its inhalation platform could expand into multiple multi-billion-dollar therapeutic markets beyond migraine.

This session is designed for biotech investors, operators, and anyone interested in how delivery innovation can unlock step-change improvements in efficacy.

Guest Speaker Dalton Signor, CEO and Cofounder, Miist Therapeutics

Moderated by: David Fleck, Founder & Managing Partner, Freeflow Ventures and Kevin Barrett, Managing Partner, Freeflow Ventures